AngioDynamics Posts Double-Digit Med Tech Growth Amid Mixed Fiscal Q3
Event summary
- AngioDynamics reported $78.4M in net sales for Q3 FY2026, up 8.9% YoY.
- Med Tech segment grew 19% YoY, driven by Auryon, AlphaVac, and NanoKnife.
- GAAP loss per share was $0.19, with adjusted EBITDA of $1.8M.
- Company raised full-year revenue guidance to $313.5M–$315.5M.
- Cash position at $37.8M, with plans to build inventory for Q4.
The big picture
AngioDynamics' Q3 results highlight the strategic shift toward higher-margin Med Tech products, offsetting challenges in the Med Device segment. The company's ability to navigate tariff headwinds and maintain operational discipline will be key as it approaches fiscal year-end. With a debt-free balance sheet and raised guidance, the focus remains on executing its growth strategy in a competitive med-tech landscape.
What we're watching
- Product Momentum
- Whether AngioDynamics can sustain double-digit growth in its Med Tech segment, particularly with Auryon and NanoKnife.
- Margin Pressures
- How tariffs and manufacturing transition costs will impact gross margins in the remaining fiscal year.
- Cash Flow Dynamics
- The pace at which AngioDynamics can return to positive cash flow generation after Q4 inventory build-up.
Related topics